A phase 3 trial of delamanid, a newer oral drug for treating multidrug-resistant tuberculosis (MDR-TB), found no statistically significant reduction in time to sputum culture conversion when compared to placebo, but that it was safe and well tolerated.
Read more at CIDRAP
Jan 7 Lancet Respir Med abstract
Jan 7 Lancet Respir Med audio file
Jan 7 Lancet Respir Med commentary